Mesalazine/acetylcysteineAlternative Names: Acetylcysteine/mesalamine; Acetylcysteine/mesalazine; ALTH12; Mesalamine/N-acetylcysteine; N-acetylcysteine/mesalamine; N-acetylcysteine/mesalazine
Latest Information Update: 03 Feb 2016
At a glance
- Originator Altheus Therapeutics
- Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Reducing agents; Small molecules; Sulfur amino acids
- Mechanism of Action Antioxidants; Free radical inhibitors; Lipoxygenase-cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Crohn's disease; Gastrointestinal disorders; Ulcerative colitis; Ulcerative proctitis